EGFR and non-small cell lung carcinoma: A phase III clinical trial (NEJ009) (26) demonstrated that gefitinib in combination with pemetrexed and carboplatin improved PFS and OS compared with EGFR-TKIs alone for untreated advanced NSCLC with classic EGFR mutations.